Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.


Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
07 2020
Historique:
received: 19 12 2019
revised: 10 02 2020
accepted: 14 02 2020
pubmed: 19 4 2020
medline: 2 7 2021
entrez: 19 4 2020
Statut: ppublish

Résumé

Among visceral metastatic sites, cutaneous melanoma (CM) metastasises initially to the liver in ~14-20% of cases. Liver metastases in CM patients are associated with both poor prognosis and poor response to immunotherapy. Histopathological growth patterns (HGPs) of liver metastases of the replacement and desmoplastic type, particularly from colorectal cancer and uveal melanoma (UM), may impart valuable biological and prognostic information. Here, we have studied HGP in 43 CM liver metastases resected from 42 CM patients along with other prognostic factors from three institutions. The HGPs (replacement, desmoplastic, pushing) were scored at the metastasis-liver interface with two algorithms: (1) 100% desmoplastic growth pattern (dHGP) and any (≥1%) replacement pattern (any-rHGP) and (2) >50% dHGP, >50% rHGP or mixed (<50% dHGP and/or rHGP, pushing HGP). For 1 patient with 2 metastases, an average was taken to obtain 1 final HGP yielding 42 observations from 42 patients. 22 cases (52%) had 100% dHGP whereas 20 (48%) had any replacement. Cases with rHGP demonstrated vascular co-option/angiotropism. With the development of liver metastasis, only rHGP (both algorithms), male gender and positive resection margins predicted diminished overall survival (p = 0.00099 and p = 0.0015; p = 0.034 and p = 0.024 respectively). On multivariate analysis, only HGP remained significant. 7 of 42 (17%) patients were alive with disease and 21 (50%) died with follow-up after liver metastases ranging from 1.8 to 42.2 months (mean: 20.4 months, median: 19.0 months). 14 (33%) patients with previously-treated metastatic disease had no evidence of disease at last follow up. In conclusion, we report for the first time replacement and desmoplastic HGPs in CM liver metastases and their prognostic value, as in UM and other solid cancers. Of particular importance, any rHGP significantly predicted diminished overall survival while 100% dHGP correlated with increased survival. These results contribute to a better understanding of the biology of CM liver metastases and potentially may be utilised in managing patients with these metastases.

Identifiants

pubmed: 32304183
doi: 10.1002/cjp2.161
pmc: PMC7339161
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

195-206

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

Références

Gastroenterol Hepatol Bed Bench. 2012 Spring;5(2):79-83
pubmed: 24834204
Science. 2001 Oct 19;294(5542):559-63
pubmed: 11577199
Nature. 2014 Mar 6;507(7490):109-13
pubmed: 24572365
Melanoma Res. 2017 Apr;27(2):134-139
pubmed: 28099368
Sci Rep. 2016 Apr 06;6:23834
pubmed: 27048955
Br J Surg. 2013 Aug;100(9):1138-47
pubmed: 23775340
Mod Pathol. 2014 Dec;27(12):1641-8
pubmed: 24851832
Nat Med. 2016 Nov;22(11):1294-1302
pubmed: 27748747
Lab Invest. 2017 Feb 27;:
pubmed: 28240745
Cancer. 2014 Mar 15;120(6):781-9
pubmed: 24301420
Development. 2015 Jun 15;142(12):2094-108
pubmed: 26081571
Angiogenesis. 2020 Feb;23(1):27-41
pubmed: 31720876
Angiogenesis. 2019 May;22(2):355-368
pubmed: 30637550
Ann Surg Oncol. 2006 May;13(5):712-20
pubmed: 16538410
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493
pubmed: 30816337
Br J Cancer. 2017 Nov 7;117(10):1427-1441
pubmed: 28982110
Ann Surg Oncol. 2019 Dec;26(13):4587-4598
pubmed: 31605342
Am J Surg Pathol. 2008 Sep;32(9):1396-403
pubmed: 18670348
Actas Dermosifiliogr. 2013 Sep;104(7):593-7
pubmed: 23876678
J Cutan Pathol. 2019 Jul;46(7):498-507
pubmed: 30903664
Pigment Cell Melanoma Res. 2013 Sep;26(5):746-54
pubmed: 23789776
Angiogenesis. 2020 Feb;23(1):43-54
pubmed: 31655928
J Pathol Clin Res. 2018 Oct;4(4):227-240
pubmed: 29917326
Jpn J Clin Oncol. 1996 Feb;26(1):24-9
pubmed: 8551663
Cancer Res. 2015 Dec 1;75(23):5014-22
pubmed: 26354021
Histopathology. 2012 Nov;61(5):889-98
pubmed: 22716270

Auteurs

Raymond Barnhill (R)

Department of Pathology, Institut Curie, Paris, France.
Department of Translational Research, Institut Curie, Paris, France.
Faculty of Medicine, University of Paris Réné Descartes, Paris, France.

Pieter-Jan van Dam (PJ)

Faculty of Medicine and Health Sciences, University of Antwerp - MIPRO Center for Oncological Research (CORE) - TCRU, GZA Sint-Augustinus, Antwerpen, Belgium.
HistoGeneX, Wilrijk, Belgium.

Peter Vermeulen (P)

Faculty of Medicine and Health Sciences, University of Antwerp - MIPRO Center for Oncological Research (CORE) - TCRU, GZA Sint-Augustinus, Antwerpen, Belgium.

Gabriel Champenois (G)

Experimental Pathology, Department of Pathology, Institut Curie, Paris, France.

André Nicolas (A)

Experimental Pathology, Department of Pathology, Institut Curie, Paris, France.

Robert V Rawson (RV)

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.

James S Wilmott (JS)

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.

John F Thompson (JF)

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.
Department of Surgery, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.

Georgina V Long (GV)

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.
Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.

Nathalie Cassoux (N)

Faculty of Medicine, University of Paris Réné Descartes, Paris, France.
Department of Ophthalmology, Institut Curie, Paris, France.

Sergio Roman-Roman (S)

Department of Translational Research, Institut Curie, Paris, France.

Klaus J Busam (KJ)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Richard A Scolyer (RA)

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, Australia.
Sydney Medical School, The University of Sydney, Sydney, Australia.

Alexander J Lazar (AJ)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Claire Lugassy (C)

Department of Translational Research, Institut Curie, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH